So far as our Directors are aware, immediately following the completion of the **[REDACTED]** and the conversion of **[REDACTED]** existing Domestic Unlisted Shares into H Shares (taking into account the Share Subdivision), and assuming the **[REDACTED]** is not exercised, the following persons are expected to have an interest in the Shares or underlying Shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO:

Name of shareholder	Nature of interest	Description of Shares	Number of Shares to be held(1)	Approximate percentage of interest in the total issued share capital of our Company as of the Latest Practicable Date	Approximate percentage of interest in the total share capital of our Company immediately following the completion of the [REDACTED](2)
Dr. Wan	Beneficial interest	H Shares	**[REDACTED]**	12.29%	**[REDACTED]**%
	Interest in controlled corporation(3)(4)	H Shares	**[REDACTED]**	19.56%	**[REDACTED]**%
	Interest of a party to an agreement regarding interest in our Company(5)	H Shares	**[REDACTED]**	2.58%	**[REDACTED]**%
Dr. Wang	Beneficial interest	H Shares	**[REDACTED]**	2.58%	**[REDACTED]**%
	Interest of a party to an agreement regarding interest in our Company(5)	H Shares	**[REDACTED]**	31.84%	**[REDACTED]**%
Lingxin Partnership	Beneficial interest	H Shares	**[REDACTED]**	17.22%	**[REDACTED]**%
	Interest of a party to an agreement regarding interest in our Company(5)	H Shares	**[REDACTED]**	17.20%	**[REDACTED]**%
Lynk Investment	Beneficial interest	H Shares	**[REDACTED]**	2.34%	**[REDACTED]**%
	Interest of a party to an agreement regarding interest in our Company(5)	H Shares	**[REDACTED]**	32.08%	**[REDACTED]**%
Hangzhou Kaitai Capital Management Co., Ltd. (杭州凱泰資本管理有限公司) ("**Kaitai Capital**")	Interest in controlled corporation(6)	H Shares	**[REDACTED]**	8.94%	**[REDACTED]**%

Name of shareholder	Nature of interest	Description of Shares	Number of Shares to be held[(1)]	Approximate percentage of interest in the total issued share capital of our Company as of the Latest Practicable Date	Approximate percentage of interest in the total share capital of our Company immediately following the completion of the [REDACTED][(2)]
Xu Yonghong (徐永紅)	Interest in controlled corporation[(6)]	H Shares	**[REDACTED]**	8.94%	**[REDACTED]**%
Health Brilliant Limited (健妙有限公司) ("**Health Brilliant**")	Beneficial interest	H Shares	**[REDACTED]**	6.71%	**[REDACTED]**%
Legend Capital Management Co., Ltd. (君聯資本管理股份有限公司) ("**Legend Capital**")	Interest in controlled corporation[(7)]	H Shares	**[REDACTED]**	8.77%	**[REDACTED]**%
Mr. Chen Hao (陳浩)	Interest in controlled corporation[(7)]	H Shares	**[REDACTED]**	8.77%	**[REDACTED]**%
Decheng LYNK Limited	Beneficial interest	H Shares	**[REDACTED]**	9.52%	**[REDACTED]**%
Xiangmin Cui	Interest in controlled corporation[(8)]	H Shares	**[REDACTED]**	9.52%	**[REDACTED]**%

Notes:

(1) All interests stated are long positions.

(2) The calculation is based on the total number of **[REDACTED]** H Shares in **[REDACTED]** immediately following the completion of the **[REDACTED]** comprising **[REDACTED]** H Shares to be **[REDACTED]** upon conversion of the same number of Domestic Unlisted Shares and **[REDACTED]** H Shares to be **[REDACTED]** pursuant to the **[REDACTED]** (assuming the Share Subdivision is completed and the **[REDACTED]** is not exercised).

(3) Dr. Wan holds approximately 65.51% of the partnership interest in Lingxin Partnership as general partner. As such, Dr. Wan is deemed to be interested in the **[REDACTED]** H Shares of the Company held by Lingxin Partnership under the SFO.

(4) Dr. Wan and Dr. Vazquez hold 26.14% and 55.60% shareholding interests in Lynk Investment respectively. Pursuant to a voting agreement dated October 29, 2025 entered into between Dr. Wan and Dr. Vazquez, Dr. Vazquez entrusted the voting rights of all shares in Lynk Investment to Dr. Wan. As such, Dr. Wan is deemed to be interested in the **[REDACTED]** H Shares of the Company held by Lynk Investment under the SFO.

(5) Dr. Wan, Dr. Wang, Lingxin Partnership, and Lynk Investment entered into two acting in concert agreements on June 30, 2021 and November 25, 2025 respectively, pursuant to which the parties agreed to act in concert in connection with their respective shareholdings in the Company (being **[REDACTED]** H Shares, **[REDACTED]** H Shares, **[REDACTED]** H Shares and **[REDACTED]** H Shares respectively immediately following the completion of the **[REDACTED]** and taking into account the Share Subdivision) and in the event of disagreement follow Dr. Wan's voting directions. Therefore, each of Dr. Wan, Dr. Wang, Lingxin Partnership and Lynk Investment is deemed to be interested in the H Shares held by each of the others under the SFO. See "Relationship with Our Single Largest Group of Shareholders – Our Single Largest Group of Shareholders" for further details.

(6) The general partner of Kaitai Chengde is Hangzhou Kaitai Jie'ao Investment Management Co., Ltd. (杭州凱泰潔奧投資管理有限公司) which is ultimately controlled by Kaitai Capital. The general partner of Kaitai Houde is Hangzhou Kaitai Runhui Investment Management Co., Ltd. (杭州凱泰潤匯投資管理有限公司) which is ultimately controlled by Kaitai Capital. The general partner of Kaitai Houde is Kaitai Runhui, which is ultimately controlled by Kaitai Capital. The general partners of Chuangyi Kaitai are Kaitai Capital and Kaitai Huijin. Kaitai Huijin is held as to 80% by Kaitai Capital. Kaitai Capital is owned as to 53% by Xu Yonghong (徐永紅). As such, each of Kaitai Capital and Xu Yonghong (徐永紅) is deemed to be interested in the **[REDACTED]** H Shares, **[REDACTED]** H Shares and **[REDACTED]** H Shares held by Kaitai Chengde, Kaitai Houde and Chuangyi Kaitai respectively under the SFO.

(7) The general partner of Junlian Huikang is Lasa Junqi Enterprise Management Co., Ltd. (拉薩君祺企業管理有限公司), which is wholly owned by Legend Capital. Health Brilliant is wholly owned by LC Healthcare Fund II, L.P. whose general partner is LC Healthcare Fund II GP Limited. LC Healthcare Fund II GP Limited is ultimately controlled by Legend Capital. Legend Capital is controlled by Beijing Junqi Jiarui Enterprise Management Co., Ltd. (北京君祺嘉睿企業管理有限公司), which is in turn held as to 40% by Mr. Chen Hao (陳浩). As such, each of Legend Capital and Mr. Chen Hao (陳浩) is deemed to be interested in the **[REDACTED]** H Shares and **[REDACTED]** H Shares held by Junlian Huikang and Health Brilliant respectively under the SFO.

(8) Decheng LYNK Limited is wholly owned by Decheng USD Fund. The general partner of Decheng USD Fund is Decheng Management, which is wholly owned by Xiangmin Cui. As such, Xiangmin Cui is deemed to be interested in the **[REDACTED]** H Shares held by Decheng LYNK Limited under the SFO.

Save as disclosed herein, our Directors are not aware of any persons who will, immediately following completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised), without taking into account the **[REDACTED]** that may be taken up under the **[REDACTED]**, have interests or short positions in Shares or underlying Shares which would fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, interested in 10% or more of the **[REDACTED]** of any other member of the Group.